(March 12, 2018, 5:49 PM EDT) -- SAN FRANCISCO — Shareholders in a securities class action lawsuit failed to plead any material misrepresentation or scienter in arguing that a drug company and certain of its senior officers and directors issued false and misleading statements about the likelihood of success for a hepatitis B (HBV) treatment drug the drug company was developing, a Ninth Circuit U.S. Court of Appeals panel ruled Feb. 15 in affirming a lower court’s dismissal ruling (In re Arrowhead Research Corp. Securities Litigation, No. 16-56499, 9th Cir., 2018 U.S. App. LEXIS 3556)....